CLClinicLens

Infectious Disease

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial. | ClinicLens

Broadly neutralizing antibodies (bnAbs) are a promising tool for HIV prevention and treatment. Here we conducted a first-in-human, phase 1 trial of the bispecific 10E8.4/iMab antibody, which consists of a 10E8.4 arm binding the HIV-1 envelope glycoprotein membrane-proximal extern

Medical Literature · Updated

← Back to articles
This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.